Related Experiment Video
Updated: Sep 14, 2025
Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
Published on: May 10, 2021
Valvular interstitial cells as a novel therapeutic target for preventing calcific aortic valve disease
Theoni Theodoropoulou1, Iordanis Mourouzis2, Athanasia Katsaouni2
1Unit for Structural Heart Diseases and Valvulopathies, First Department of Cardiology, Athens School of Medicine, Hippokration Hospital, Athens, Greece.
Insights
Calcific aortic valve disease (CAVD) is a prevalent condition in the elderly, with valvular interstitial cells playing a key role in its development. Understanding these cells is crucial for developing new treatments to prevent aortic valve calcification.
Area of Science:
- Cardiovascular Medicine
- Cell Biology
- Biochemistry
Background:
- Calcific aortic valve disease (CAVD) is a common, poorly understood condition in the elderly.
- Current treatments like aortic valve replacement (AVR) have drawbacks and rising healthcare costs.
- No pharmacological therapies exist to prevent aortic valve calcification.
Purpose of the Study:
- To review the inflammatory and calcific pathways in CAVD.
- To highlight the critical role of valvular interstitial cells (VICs) in CAVD pathogenesis.
- To identify potential therapeutic targets for preventing valvular calcification.
Main Methods:
- Literature review of established inflammatory and calcific pathways in CAVD.
- Focus on the molecular mechanisms of valvular interstitial cell (VIC) dysfunction.
- Analysis of VIC apoptosis and osteoblastic differentiation in relation to calcification.
Main Results:
- Dysregulated VICs are a key driver of CAVD.
- VICs contribute to calcification through apoptosis and osteoblastic differentiation.
- VICs produce bone-related proteins that influence calcium deposition.
Conclusions:
- VICs are central to the development of CAVD.
- Targeting VIC pathways may offer new therapeutic strategies.
- Further research into VIC biology is needed to develop preventative treatments for aortic valve calcification.
Abstract:
Calcific aortic valve disease (CAVD) is a common heart valve disease among elderly individuals, and despite its prevalence, the causal mechanisms behind CAVD development remain poorly understood. The current standard treatment for symptomatic aortic stenosis is surgical or transcatheter aortic valve replacement (AVR). Nevertheless, surgical interventions come with disadvantages such as lifelong anticoagulation therapy in patients with mechanical valves and high rates of reoperation due to valve degeneration in adults or somatic growth in pediatric patients. To date, no pharmacological therapy has been established to prevent aortic valve calcification. The increased life expectancy combined with AVR has led to a significant rise in healthcare costs. Annual Medicare payments for patients with aortic stenosis in the US increased from 2.9 billion in 2010 to 4.6 billion in 2019, a difference of more than 1.7 billion dollars. Hence there is a demand for new drugs to prevent the development of valvular calcification. Ongoing clinical trials are currently exploring new potential treatments, targeting molecular pathways associated with calcification in aortic stenosis. It is known that dysregulation of the valvular interstitial cells (VICs) that populate the valve matrix is a key driver of the pathology. VICs undergo apoptosis or osteoblastic differentiation, and by producing bone-related proteins, including, osteocalcin, osteopontin, and alkaline phosphatase, they ultimately influence calcium deposition and contribute to the calcification process. This review aims to outline the established inflammatory and calcific pathways involved in CAVD, with a particular focus on the role of valvular interstitial cells.
